Frontiers in cardiovascular medicine · 2026
Cardiac surgery in an infant hemophilia B carrier with moderate hemophilia: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hölz Julia, Nobile Chiara, Holzapfel Johannes, Lieftüchter Victoria, De Winkel Nicole, Olivieri Martin
Аннотация
INTRODUCTION: This is the first reported case of a female infant with moderate hemophilia B undergoing complex cardiac surgery, highlighting challenges in managing bleeding disorders in this rare clinical setting.
PATIENT CONCERNS AND CLINICAL FINDINGS: A 4-month-old girl with Trisomy 21 was found to have moderate hemophilia B and an atrioventricular septal defect requiring surgery.
DIAGNOSIS INTERVENTIONS AND OUTCOMES: Genetic testing confirmed hemophilia B. Surgery was performed successfully using extended half-life recombinant factor IX (rFIX-FP) to maintain stable coagulation. The patient experienced no excessive bleeding and recovered well.
CONCLUSION: This case demonstrates that extended half-life FIX products enable safe and effective management of moderate hemophilia B during complex cardiac surgery in infants. Individualized perioperative planning and interdisciplinary collaboration are essential for optimal outcomes.
PATIENT CONCERNS AND CLINICAL FINDINGS: A 4-month-old girl with Trisomy 21 was found to have moderate hemophilia B and an atrioventricular septal defect requiring surgery.
DIAGNOSIS INTERVENTIONS AND OUTCOMES: Genetic testing confirmed hemophilia B. Surgery was performed successfully using extended half-life recombinant factor IX (rFIX-FP) to maintain stable coagulation. The patient experienced no excessive bleeding and recovered well.
CONCLUSION: This case demonstrates that extended half-life FIX products enable safe and effective management of moderate hemophilia B during complex cardiac surgery in infants. Individualized perioperative planning and interdisciplinary collaboration are essential for optimal outcomes.